0001209191-19-052836.txt : 20191009 0001209191-19-052836.hdr.sgml : 20191009 20191009171212 ACCESSION NUMBER: 0001209191-19-052836 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191008 FILED AS OF DATE: 20191009 DATE AS OF CHANGE: 20191009 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vaughn James J CENTRAL INDEX KEY: 0001649689 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51541 FILM NUMBER: 191144888 MAIL ADDRESS: STREET 1: C/O GENOMIC HEALTH, INC. STREET 2: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENOMIC HEALTH INC CENTRAL INDEX KEY: 0001131324 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770552594 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-556-9300 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-10-08 0 0001131324 GENOMIC HEALTH INC GHDX 0001649689 Vaughn James J 301 PENOBSCOT DRIVE REDWOOD CITY CA 94063 0 1 0 0 Chief Commercial Officer Common Stock 2019-10-08 4 M 0 4500 33.21 A 20917 D Common Stock 2019-10-08 4 S 0 4500 67.7501 D 16417 D Employee Stock Option (right to buy) Holding 33.21 2019-10-08 4 M 0 4500 0.00 D 2028-01-31 Common Stock 4500 39707 D Includes an aggregate of 11,281 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 11, 2019. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Represents weighted average sale price. Actual sale prices ranged from $67.46 to $68.29. The option became exercisable as to 25% of the shares on January 31, 2019, and becomes exercisable as to 1/48th of the shares each full month thereafter. /s/ Jason W. Radford, Attorney-in-fact 2019-10-09